Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Infection

• Publication date

  1996-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/BF01713041PMID 9007588
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma

  1996cited by this paper
• The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin

  1996cited by this paper
• Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

  1995cited by this paper
• Antiviral therapy for human immunodeficiency virus infections

  1995cited by this paper
• Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds

  1995cited by this paper
• Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine

  1995cited by this paper
• Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance

  1995cited by this paper
• Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy

  1995cited by this paper
• Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.

  1994cited by this paper
• Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

  1994cited by this paper
• Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions

  1994cited by this paper
• Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

  1994influential reference
• Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.

  1993cited by this paper
• pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

  1993cited by this paper
• Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species.

  1993cited by this paper
• Clinical correlates of in vitro HIV‐1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial

  1993cited by this paper
• Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS.

  1993cited by this paper
• A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

  1993cited by this paper
• Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

  1993cited by this paper
• Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

  1993cited by this paper
• Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates

  1993cited by this paper
• Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.

  1993cited by this paper
• 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

  1993cited by this paper
• Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.

  1993cited by this paper
• Sequence analysis of an HIV‐1 isolate which displays unusually high‐level AZT resistance in vitro

  1992cited by this paper
• HIV-1 sensitivity to zidovudine and clinical outcome in children.

  1992cited by this paper
• Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens

  1992cited by this paper
• In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.

  1992cited by this paper
• Quantitation of targets for PCR by use of limiting dilution.

  1992cited by this paper
• Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease

  1992cited by this paper
• 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

  1992cited by this paper
• Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

  1992cited by this paper
• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

  1992influential reference
• In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine

  1992cited by this paper
• Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.

  1992cited by this paper
• Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera

  1992cited by this paper
• In Vivo Prevalence of Azidothymidine (AZT) Resistance Mutations in an AIDS Patient Before and After AZT Therapy

  1991cited by this paper
• Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

  1991cited by this paper
• Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture

  1991influential reference
• Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

  1991influential reference
• Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.

  1990cited by this paper
• Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

  1990cited by this paper
• A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR)

  1990cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy

  1989cited by this paper
• Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

  1989influential reference
• 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

  1985cited by this paper

• Lack of evidence for an association between seminoma and human papillomavirus infection using GP5+/GP6+ consensus primers

  2013cites this paper
• Low prevalence of human papillomavirus infection in the healthy oral mucosa of a Northern Italian population.

  2012cites this paper
• Does HPV play a role in the etiopathogenesis of ameloblastoma? An immunohistochemical, in situ hybridization and polymerase chain reaction study of 18 cases using laser capture microdissection

  2005cites this paper
• Search for viruses in the CSF of patients with acute neurological disorders: possible involvement of beta-and gamma-herpesviruses.

  2004cites this paper
• Analysis of the HIV‐1 nef gene in five intravenous drug users with long‐term nonprogressive HIV‐1 infection in Italy

  2000cites this paper
• Clinical Evaluation of an In-House Reverse Transcription-Competitive PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma

  1999cites this paper
• Genotypic Resistance to Zidovudine as a Predictor of Failure of Subsequent Therapy with Human Immunodeficiency Virus Type-1 Nucleoside Reverse-Transcriptase Inhibitors

  1999cites this paper
• Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.

  1999cites this paper
• Impact of HIV Type 1 Subtype Variation on Viral RNA Quantitation

  1999cites this paper
• Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.

  1999cites this paper
• Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors

  1998cites this paper
• Zidovudine Therapy and HIV Type 1 Mutations in Children with Symptomatic HIV Type 1 Infection: Effect of Switching to Didanosine or Zidovudine Plus Didanosine Therapy

  1998cites this paper